Nu-Med Plus (NUMD) Profit After Tax Growth (3y) (2015 - 2025)
Nu-Med Plus (NUMD) Profit After Tax Growth (3y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.90 Bn | 193.29 Bn | 7.27 Bn | -12.28% |
| 2 | Stryker | 129.12 Bn | 125.64 Bn | 4.50 Bn | 20.02% |
| 3 | Medtronic | 119.32 Bn | 110.10 Bn | 6.41 Bn | 1.93% |
| 4 | Boston Scientific | 73.63 Bn | 73.09 Bn | 3.85 Bn | 49.66% |
| 5 | Edwards Lifesciences | 52.14 Bn | 47.89 Bn | 1.35 Bn | -7.65% |
| 6 | Dexcom | 34.48 Bn | 32.54 Bn | 830.00 Mn | 29.05% |
| 7 | GE HealthCare Technologies | 34.06 Bn | 31.95 Bn | 2.18 Bn | 9.79% |
| 8 | Koninklijke Philips | 26.40 Bn | 23.08 Bn | 4.55 Bn | 97.37% |
| 9 | Steris | 23.17 Bn | 22.69 Bn | 684.20 Mn | 15.46% |
| 10 | Nu-Med Plus | 2.03 Mn | 2.02 Mn | - | 41.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -31.93% |
| Sep 30, 2025 | 40.93% |
| Jun 30, 2025 | 41.43% |
| Mar 31, 2025 | 29.40% |
| Dec 31, 2024 | 54.54% |
| Sep 30, 2024 | 45.96% |
| Jun 30, 2024 | 58.54% |
| Mar 31, 2024 | 60.60% |
| Dec 31, 2023 | 51.41% |
| Sep 30, 2023 | 66.93% |
| Jun 30, 2023 | 70.09% |
| Mar 31, 2023 | 43.13% |
| Dec 31, 2022 | 30.12% |
| Sep 30, 2022 | 27.22% |
| Jun 30, 2022 | 38.38% |
| Mar 31, 2022 | 49.04% |
| Dec 31, 2021 | 30.93% |
| Sep 30, 2021 | 39.21% |
| Jun 30, 2021 | -11.81% |
| Mar 31, 2021 | -34.24% |